Abstract
Spasticity is a chronic condition causing deformity and pain, resulting in a detrimental impact on patients’ quality of life (QoL) as well as increased costs to the healthcare system. In Australia, Dysport® (abobotulinumtoxin, aboBoNTA) is indicated for adult lower (ALL) and upper limb spasticity. Clinical evidence demonstrated that early intervention with aboBoNTA leads to better clinical outcomes. This analysis aims to assess cost-effectiveness of an early aboBoNTA intervention versus best supportive care (BCS) in improvement of functional outcomes and quality of life in ALL.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
